Nifty
Sensex
:
:
20267.90
67481.19
134.75 (0.67%)
492.75 (0.74%)

Pharmaceuticals & Drugs

Rating :
55/99

BSE: 526953 | NSE: VENUSREM

386.55
01-Dec-2023
  • Open
  • High
  • Low
  • Previous Close
  •  387.00
  •  405.00
  •  383.10
  •  386.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  213514
  •  838.58
  •  407.05
  •  145.80

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 516.30
  • 20.27
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 490.36
  • N/A
  • 1.10

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 41.76%
  • 1.92%
  • 48.21%
  • FII
  • DII
  • Others
  • 1.03%
  • 0.00%
  • 7.08%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.25
  • 11.53
  • 0.45

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -7.98
  • 13.11
  • 2.28

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -8.46
  • -
  • -24.51

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.24
  • 6.89
  • 11.33

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.46
  • 0.59
  • 0.86

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.66
  • 7.14
  • 6.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Net Sales
167.72
139.89
19.89%
95.15
143.08
-33.50%
155.64
142.45
9.26%
116.90
124.34
-5.98%
Expenses
149.93
126.92
18.13%
84.75
128.57
-34.08%
131.03
136.91
-4.29%
108.80
111.91
-2.78%
EBITDA
17.79
12.97
37.16%
10.40
14.51
-28.33%
24.61
5.54
344.22%
8.10
12.43
-34.84%
EBIDTM
10.61%
9.27%
10.93%
10.14%
15.81%
3.89%
6.93%
10.00%
Other Income
3.05
1.79
70.39%
2.26
1.44
56.94%
3.41
2.25
51.56%
3.81
1.22
212.30%
Interest
0.06
0.00
0
0.06
0.26
-76.92%
0.00
0.00
0
0.15
0.31
-51.61%
Depreciation
6.44
8.99
-28.36%
7.55
7.80
-3.21%
8.29
7.56
9.66%
7.22
8.64
-16.44%
PBT
14.34
5.77
148.53%
5.05
7.89
-35.99%
19.73
0.23
8,478.26%
4.54
4.70
-3.40%
Tax
4.40
0.44
900.00%
3.87
1.00
287.00%
8.67
0.00
0
1.25
-0.95
-
PAT
9.94
5.33
86.49%
1.18
6.89
-82.87%
11.06
0.23
4,708.70%
3.29
5.65
-41.77%
PATM
5.93%
3.81%
1.24%
4.82%
7.11%
0.16%
2.81%
4.54%
EPS
7.43
3.99
86.22%
0.88
5.15
-82.91%
8.27
0.17
4,764.71%
2.46
4.23
-41.84%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
535.41
555.51
600.18
548.12
339.33
321.89
372.41
400.04
418.27
463.99
541.56
Net Sales Growth
-2.61%
-7.44%
9.50%
61.53%
5.42%
-13.57%
-6.91%
-4.36%
-9.85%
-14.32%
 
Cost Of Goods Sold
302.76
330.99
386.98
340.79
174.31
181.95
205.08
227.07
238.51
268.94
300.00
Gross Profit
232.65
224.51
213.20
207.33
165.02
139.94
167.33
172.97
179.77
195.05
241.55
GP Margin
43.45%
40.42%
35.52%
37.83%
48.63%
43.47%
44.93%
43.24%
42.98%
42.04%
44.60%
Total Expenditure
474.51
495.31
538.07
494.35
298.52
289.37
332.94
349.32
337.11
374.81
403.33
Power & Fuel Cost
-
5.52
4.71
4.58
4.73
4.86
4.29
4.14
4.01
3.80
3.38
% Of Sales
-
0.99%
0.78%
0.84%
1.39%
1.51%
1.15%
1.03%
0.96%
0.82%
0.62%
Employee Cost
-
57.05
52.33
46.02
46.02
42.10
39.31
34.27
32.44
32.36
30.45
% Of Sales
-
10.27%
8.72%
8.40%
13.56%
13.08%
10.56%
8.57%
7.76%
6.97%
5.62%
Manufacturing Exp.
-
32.40
31.57
22.86
20.84
21.01
36.10
42.48
15.70
17.29
22.10
% Of Sales
-
5.83%
5.26%
4.17%
6.14%
6.53%
9.69%
10.62%
3.75%
3.73%
4.08%
General & Admin Exp.
-
20.70
16.67
16.45
17.57
11.85
13.52
13.26
11.97
15.67
14.74
% Of Sales
-
3.73%
2.78%
3.00%
5.18%
3.68%
3.63%
3.31%
2.86%
3.38%
2.72%
Selling & Distn. Exp.
-
48.40
45.80
63.64
35.05
27.60
34.65
28.10
34.48
36.75
32.65
% Of Sales
-
8.71%
7.63%
11.61%
10.33%
8.57%
9.30%
7.02%
8.24%
7.92%
6.03%
Miscellaneous Exp.
-
0.26
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
32.65
% Of Sales
-
0.05%
0%
0%
0%
0%
0%
0%
0%
0%
0%
EBITDA
60.90
60.20
62.11
53.77
40.81
32.52
39.47
50.72
81.16
89.18
138.23
EBITDA Margin
11.37%
10.84%
10.35%
9.81%
12.03%
10.10%
10.60%
12.68%
19.40%
19.22%
25.52%
Other Income
12.53
10.32
8.31
19.63
5.31
6.09
2.39
4.28
2.01
0.68
0.47
Interest
0.27
0.29
0.48
13.02
13.34
25.41
35.56
36.38
37.98
41.21
29.40
Depreciation
29.50
32.30
33.53
35.28
32.01
33.98
33.83
40.26
41.68
46.00
40.22
PBT
43.66
37.93
36.41
25.11
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
Tax
18.19
11.36
-4.32
-13.21
1.96
-1.15
3.16
-4.56
1.81
-2.51
4.78
Tax Rate
41.66%
29.95%
-11.86%
-27.21%
-24.41%
3.87%
-11.48%
21.07%
51.57%
-94.72%
6.92%
PAT
25.47
26.57
40.72
61.77
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
PAT before Minority Interest
25.47
26.57
40.72
61.77
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
4.76%
4.78%
6.78%
11.27%
-2.95%
-8.88%
-8.24%
-4.27%
0.41%
1.11%
11.87%
PAT Growth
40.72%
-34.75%
-34.08%
-
-
-
-
-
-67.05%
-91.98%
 
EPS
19.01
19.83
30.39
46.10
-7.46
-21.32
-22.90
-12.75
1.27
3.85
47.99

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
460.34
440.45
400.28
323.37
332.52
361.91
388.67
437.62
456.68
461.61
Share Capital
13.37
13.37
12.34
12.34
12.34
12.34
12.34
11.44
11.44
11.44
Total Reserves
446.97
427.08
374.19
311.03
320.18
349.57
376.33
426.18
445.24
450.17
Non-Current Liabilities
58.17
45.95
58.12
95.82
136.68
158.47
179.52
212.05
221.55
161.75
Secured Loans
0.00
0.00
0.09
24.19
61.29
86.60
112.69
134.57
150.95
114.76
Unsecured Loans
38.68
38.68
46.74
47.87
54.73
50.84
49.13
56.47
51.34
25.22
Long Term Provisions
8.85
7.95
7.38
6.63
5.32
4.50
4.29
3.79
3.78
3.31
Current Liabilities
82.57
92.74
97.45
224.58
263.62
230.38
196.81
193.14
162.83
210.99
Trade Payables
50.84
50.17
71.36
36.70
36.00
29.33
29.73
25.14
29.56
31.22
Other Current Liabilities
27.23
37.76
21.10
101.70
110.30
78.47
46.16
42.71
15.96
54.70
Short Term Borrowings
3.61
4.06
4.30
85.58
112.80
121.26
119.16
123.32
115.40
110.08
Short Term Provisions
0.89
0.75
0.68
0.61
4.52
1.32
1.76
1.97
1.91
14.99
Total Liabilities
601.08
579.14
555.85
643.77
732.82
750.76
765.00
842.81
841.06
834.35
Net Block
215.96
240.94
261.68
289.37
364.45
389.20
406.18
452.48
443.65
439.46
Gross Block
603.75
612.50
616.32
623.96
707.02
702.77
686.50
679.57
641.12
587.38
Accumulated Depreciation
387.78
371.57
354.63
334.59
342.57
313.57
280.32
227.09
197.47
147.93
Non Current Assets
278.12
301.10
321.82
349.77
467.39
490.50
505.60
565.75
607.85
562.24
Capital Work in Progress
26.10
25.23
25.11
24.63
64.76
64.76
66.25
80.37
78.30
67.80
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
33.95
33.36
35.03
35.77
38.18
36.53
33.17
32.90
85.91
54.98
Other Non Current Assets
2.11
1.57
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
322.96
278.04
234.03
294.00
265.43
260.27
259.41
277.07
233.21
272.11
Current Investments
20.13
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
119.94
125.64
119.99
141.12
142.73
138.17
140.60
143.29
142.87
142.26
Sundry Debtors
76.66
38.60
32.04
30.69
38.04
47.27
47.29
61.59
63.22
64.99
Cash & Bank
53.72
50.40
31.42
2.13
2.81
3.98
3.56
7.07
3.62
4.41
Other Current Assets
52.51
5.01
5.70
55.72
81.85
70.84
67.96
65.12
23.51
60.47
Short Term Loans & Adv.
50.73
58.39
44.88
64.34
76.70
66.00
67.96
65.12
23.51
60.47
Net Current Assets
240.39
185.30
136.59
69.43
1.81
29.88
62.59
83.93
70.38
61.12
Total Assets
601.08
579.14
555.85
643.77
732.82
750.77
765.01
842.82
841.06
834.35

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
36.63
41.10
131.84
77.60
45.33
31.19
58.93
46.88
67.80
52.65
PBT
37.93
36.41
25.11
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
Adjustment
23.33
26.33
21.89
41.56
60.72
66.24
70.61
56.41
83.56
37.21
Changes in Working Capital
-24.63
-21.64
61.39
20.82
5.37
-7.52
9.96
-13.04
-18.40
-53.65
Cash after chg. in Working capital
36.63
41.10
108.39
63.16
45.33
31.19
58.93
46.88
67.80
52.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
23.44
14.44
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-50.83
-16.73
56.49
-4.75
-11.33
-11.48
-18.32
2.92
-67.18
-94.66
Net Fixed Assets
8.82
3.42
7.56
124.42
-5.05
-11.74
18.95
-50.18
-67.39
-93.77
Net Investments
-20.13
0.00
0.00
0.00
0.00
28.60
0.00
0.00
0.00
0.00
Others
-39.52
-20.15
48.93
-129.17
-6.28
-28.34
-37.27
53.10
0.21
-0.89
Cash from Financing Activity
-0.57
-9.48
-162.24
-73.00
-35.17
-39.23
-44.13
-46.35
-1.42
40.06
Net Cash Inflow / Outflow
-14.77
14.90
26.09
-0.15
-1.17
-19.52
-3.51
3.46
-0.79
-1.95
Opening Cash & Equivalents
43.26
28.88
1.94
2.03
3.98
0.00
7.07
3.62
4.41
6.36
Closing Cash & Equivalent
21.21
43.26
28.88
1.94
2.81
-19.52
3.56
7.07
3.62
4.41

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
344.38
329.50
313.18
262.01
269.42
293.23
314.92
382.47
399.13
403.43
ROA
4.50%
7.18%
10.30%
-1.45%
-3.85%
-4.05%
-2.12%
0.20%
0.62%
8.29%
ROE
5.90%
9.85%
17.40%
-3.05%
-8.23%
-8.18%
-4.13%
0.38%
1.12%
15.38%
ROCE
7.75%
7.89%
12.37%
0.90%
-0.67%
1.17%
2.00%
5.35%
5.74%
14.06%
Fixed Asset Turnover
0.91
0.98
0.88
0.51
0.46
0.54
0.59
0.63
0.76
0.99
Receivable days
37.87
21.48
20.89
36.97
48.37
46.34
49.67
54.45
50.42
37.72
Inventory Days
80.68
74.69
86.94
152.66
159.26
136.61
129.51
124.86
112.15
90.94
Payable days
55.69
57.31
57.86
42.82
37.91
30.30
26.74
26.74
27.25
21.28
Cash Conversion Cycle
62.86
38.86
49.96
146.80
169.72
152.65
152.44
152.57
135.32
107.37
Total Debt/Equity
0.09
0.10
0.13
0.68
0.90
0.85
0.80
0.77
0.70
0.63
Interest Cover
129.84
76.69
4.73
0.40
-0.17
0.23
0.41
1.09
1.06
3.35

News Update:


  • Venus Remedies secures ‘Three Star Export House’ certificate from Government of India
    6th Nov 2023, 09:49 AM

    To attain this prestigious Three Star status, a company must demonstrate a significant export performance, reaching a milestone of $100 million in a span of three years

    Read More
  • Venus Remedies wins FICCI Healthcare Award 2023
    1st Nov 2023, 09:52 AM

    The company has won Award in the esteemed ‘Excellence in Patient Safety and Care’ category

    Read More
  • Venus Remedies achieves market authorization for Bleomycin in United Kingdom
    26th Oct 2023, 12:07 PM

    This remarkable milestone not only expands the pharma giant's global presence but also underscores its commitment to advancing cancer care

    Read More
  • Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines
    16th Oct 2023, 09:49 AM

    With this, Venus Remedies has secured 525 marketing approvals for its oncology products across 76 Countries

    Read More
  • Venus Remedies expands global reach with launch of Elores in Ecuador
    12th Oct 2023, 15:39 PM

    Additionally, the dossier has also been submitted in around 15 countries for getting the marketing authorisations

    Read More
  • Venus Remedies secures marketing authorization from Serbia for gemcitabine and docetaxel
    20th Sep 2023, 11:29 AM

    With this, the company has secured 511 marketing approvals for its oncology products across 66 countries

    Read More
  • Venus Remedies registers with DSIR to avail custom duty exemption
    14th Sep 2023, 14:10 PM

    This registration with DSIR exemplifies Venus Remedies' dedication to fostering innovation and making healthcare solutions more accessible

    Read More
  • Venus Remedies gets marketing approval from Saudi Arabia for Enoxaparin in pre-filled syringes
    28th Aug 2023, 14:09 PM

    The company has an annual capacity of producing more than 5 million units of Enoxaparin, a widely used anticoagulant that prevents blood clots, at its robotic line

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.